Company registration number 08835363 (England and Wales)
HISTOCYTE LABORATORIES LTD
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
HISTOCYTE LABORATORIES LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
HISTOCYTE LABORATORIES LTD
BALANCE SHEET
AS AT 31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
408,485
179,131
Current assets
Stocks
117,220
90,354
Debtors
4
624,784
415,299
Cash at bank and in hand
2,979,210
2,371,532
3,721,214
2,877,185
Creditors: amounts falling due within one year
5
(365,608)
(454,257)
Net current assets
3,355,606
2,422,928
Total assets less current liabilities
3,764,091
2,602,059
Provisions for liabilities
(66,907)
(38,619)
Net assets
3,697,184
2,563,440
Capital and reserves
Called up share capital
111
111
Profit and loss reserves
3,697,073
2,563,329
Total equity
3,697,184
2,563,440

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 1 April 2026 and are signed on its behalf by:
Mr C Tristram
Director
Company registration number 08835363 (England and Wales)
HISTOCYTE LABORATORIES LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
1
Accounting policies
Company information

Histocyte Laboratories Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Q10, Neon, Suite 11, Quorum Business Park, Newcastle upon Tyne, Tyne and Wear, England, NE12 8BU.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover represents net invoiced provision of design, preparation and testing services and supplies. Income is recognised as the work progresses and the company receives the right to income through performance.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
Over the term of the lease
Lab equipment
at varying rates on cost
Fixtures and fittings
20% on cost
Computer equipment
20% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.4
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

HISTOCYTE LABORATORIES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 3 -
1.5
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.6
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.7
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

1.8
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
21
16
HISTOCYTE LABORATORIES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 4 -
3
Tangible fixed assets
Leasehold improvements
Lab equipment
Fixtures and fittings
Computer equipment
Total
£
£
£
£
£
Cost
At 1 January 2025
72,162
173,885
23,992
14,329
284,368
Additions
181,903
70,273
10,125
21,513
283,814
Disposals
-
0
-
0
-
0
(4,701)
(4,701)
At 31 December 2025
254,065
244,158
34,117
31,141
563,481
Depreciation and impairment
At 1 January 2025
40,237
47,600
11,038
6,362
105,237
Depreciation charged in the year
22,254
19,381
4,980
3,144
49,759
At 31 December 2025
62,491
66,981
16,018
9,506
154,996
Carrying amount
At 31 December 2025
191,574
177,177
18,099
21,635
408,485
At 31 December 2024
31,925
126,285
12,954
7,967
179,131
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
575,169
383,823
Prepayments and accrued income
49,615
31,476
624,784
415,299
5
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
49,016
39,558
Corporation tax
36,108
180,791
Other taxation and social security
57,014
48,061
Other creditors
29,442
18,513
Accruals and deferred income
194,028
167,334
365,608
454,257
6
Operating lease commitments
As lessee
HISTOCYTE LABORATORIES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
6
Operating lease commitments
(Continued)
- 5 -

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
Total commitments
331,249
159,741
7
Parent company

The company is the subsidiary is under the control of Investor Ab (Investor Aktibolag).

8
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2025 and of its profit for the year then ended;

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- have been prepared in accordance with the requirements of the Companies Act 2006.

Senior Statutory Auditor:
Michael T Moran BA FCA
Statutory Auditor:
Robson Laidler Accountants Limited
Date of audit report:
2 April 2026
2025-12-31 2025-01-01 false false false 02 April 2026 CCH Software CCH Accounts Production 2025.300 No description of principal activity Mr C Tristram Miss I F Hofverberg 08835363 2025-01-01 2025-12-31 08835363 2025-12-31 08835363 2024-12-31 08835363 core:LeaseholdImprovements 2025-12-31 08835363 core:PlantMachinery 2025-12-31 08835363 core:FurnitureFittings 2025-12-31 08835363 core:ComputerEquipment 2025-12-31 08835363 core:LeaseholdImprovements 2024-12-31 08835363 core:PlantMachinery 2024-12-31 08835363 core:FurnitureFittings 2024-12-31 08835363 core:ComputerEquipment 2024-12-31 08835363 core:CurrentFinancialInstruments 2025-12-31 08835363 core:CurrentFinancialInstruments 2024-12-31 08835363 core:ShareCapital 2025-12-31 08835363 core:ShareCapital 2024-12-31 08835363 core:RetainedEarningsAccumulatedLosses 2025-12-31 08835363 core:RetainedEarningsAccumulatedLosses 2024-12-31 08835363 bus:Director1 2025-01-01 2025-12-31 08835363 core:LeaseholdImprovements 2025-01-01 2025-12-31 08835363 core:PlantMachinery 2025-01-01 2025-12-31 08835363 core:FurnitureFittings 2025-01-01 2025-12-31 08835363 core:ComputerEquipment 2025-01-01 2025-12-31 08835363 2024-01-01 2024-12-31 08835363 core:LeaseholdImprovements 2024-12-31 08835363 core:PlantMachinery 2024-12-31 08835363 core:FurnitureFittings 2024-12-31 08835363 core:ComputerEquipment 2024-12-31 08835363 2024-12-31 08835363 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 08835363 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 08835363 bus:FRS102 2025-01-01 2025-12-31 08835363 bus:Audited 2025-01-01 2025-12-31 08835363 bus:Director2 2025-01-01 2025-12-31 08835363 bus:FullAccounts 2025-01-01 2025-12-31 xbrli:pure xbrli:shares iso4217:GBP